Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Trip.com Group Ltd — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $13.42 (market cap $5.85B), while Trip.com Group Ltd trades at $38.62 (market cap $24.30B). The key difference: Trip.com Group Ltd is far larger — about 4.2× Iovance Biotherapeutics Inc. Common Stock's market cap, and Trip.com Group Ltd pays a 0.42% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Trip.com Group Ltd for 79 Days on average.
| IOVA | TCOM | |
|---|---|---|
Market Cap | $5.85B | $24.30B |
Volume | 14,517,176 | 1,885,560 |
Sector | Health | Consumer Cyclical |
52-Week High | $14.82 | $78.96 |
52-Week Low | $1.81 | $37.96 |
Typical Hold Time | 0 Days | 79 Days |
Enterprise Value | $5.78B | $16.46B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Trip.com (TCOM) trades at $37.96, down 0.78% on the day, amid a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 36.9% net income margin and trades at a low P/E of 7.36. Recent Q2 2026 earnings beat expectations, yet regulatory pressures and a challenging travel environment create headwinds. Analyst consensus remains strongly bullish with a $56.64 price target, indicating significant upside potential from current levels.
The outlook for TCOM balances strong earnings growth and attractive valuation against regulatory risks and market volatility. Investment opportunity lies in its dominant travel platform and international expansion, but investors face risks from antitrust penalties and competitive pressures. The stock's current discount to analyst targets presents a potential value opportunity if execution remains solid.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
